<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2010</study_start_year><data_sharing_plan>IPD Sharing (as of September 2018): No</data_sharing_plan><condition>Metastatic Colorectal Cancer</condition><condition>Advanced solid tumors</condition><condition>Colorectal Neoplasms</condition><disease>Metastatic Colorectal Cancer</disease><disease>Advanced Solid Tumors</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2088653</full_dataset_link><location>Belgium</location><location>United States</location><location>Spain</location><study_start_month>3</study_start_month><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Sym004 in Patients With Advanced Solid Tumors</name><description>This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.</description><dates><creation>2010-03-15</creation></dates><accession>2088653</accession><cross_references><ClinicalTrials___gov>NCT01117428</ClinicalTrials___gov><EU Clinical Trials Register>2009-017119-13</EU Clinical Trials Register></cross_references></HashMap>